Haddadi N, Mande P, Brodeur T, Hao K, Ryan G, Moses S
Front Immunol. 2022; 13:883375.
PMID: 35833127
PMC: 9271959.
DOI: 10.3389/fimmu.2022.883375.
Fujioka K, Kasahara A, Kida T, Fujii W, Seno T, Wada M
Allergy Asthma Clin Immunol. 2022; 18(1):63.
PMID: 35818067
PMC: 9275025.
DOI: 10.1186/s13223-022-00703-0.
Idborg H, Oke V
Int J Mol Sci. 2021; 22(21).
PMID: 34768756
PMC: 8582965.
DOI: 10.3390/ijms222111327.
Gupta S, Kaplan M
J Clin Invest. 2021; 131(3).
PMID: 33529160
PMC: 7843222.
DOI: 10.1172/JCI144918.
Oke V, Gunnarsson I, Dorschner J, Eketjall S, Zickert A, Niewold T
Arthritis Res Ther. 2019; 21(1):107.
PMID: 31036046
PMC: 6489203.
DOI: 10.1186/s13075-019-1878-y.
Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis.
Boedigheimer M, Martin D, Amoura Z, Sanchez-Guerrero J, Romero-Diaz J, Kivitz A
Lupus Sci Med. 2017; 4(1):e000226.
PMID: 29018537
PMC: 5604705.
DOI: 10.1136/lupus-2017-000226.
Safety, Tolerability, and Immunogenicity of Interferons.
Tovey M, Lallemand C
Pharmaceuticals (Basel). 2016; 3(4):1162-1186.
PMID: 27713294
PMC: 4034027.
DOI: 10.3390/ph3041162.
T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.
Raphael I, Nalawade S, Eagar T, Forsthuber T
Cytokine. 2014; 74(1):5-17.
PMID: 25458968
PMC: 4416069.
DOI: 10.1016/j.cyto.2014.09.011.
Th2 skewing by activation of Nrf2 in CD4(+) T cells.
Rockwell C, Zhang M, Fields P, Klaassen C
J Immunol. 2012; 188(4):1630-7.
PMID: 22250088
PMC: 3273574.
DOI: 10.4049/jimmunol.1101712.
Reduced expression of TCR zeta is involved in the abnormal production of cytokines by peripheral T cells of patients with systemic lupus erythematosus.
Yoshimoto K, Setoyama Y, Tsuzaka K, Abe T, Takeuchi T
J Biomed Biotechnol. 2010; 2010.
PMID: 20936133
PMC: 2947188.
DOI: 10.1155/2010/509021.
Clinical Use of Interferon-gamma.
Miller C, Maher S, Young H
Ann N Y Acad Sci. 2010; 1182:69-79.
PMID: 20074276
PMC: 6574079.
DOI: 10.1111/j.1749-6632.2009.05069.x.
Autoimmune disease: is it a disorder of the microenvironment?.
El-Badri N, Hakki A, Ferrari A, Shamekh R, Good R
Immunol Res. 2008; 41(1):79-86.
PMID: 18506645
DOI: 10.1007/s12026-007-0053-8.
Current topics in human SLE genetics.
Wong M, Tsao B
Springer Semin Immunopathol. 2006; 28(2):97-107.
PMID: 16941108
DOI: 10.1007/s00281-006-0031-6.
Enhanced expression of interferon-inducible protein 10 associated with Th1 profiles of chemokine receptor in autoimmune pulmonary inflammation of MRL/lpr mice.
Shiozawa F, Kasama T, Yajima N, Odai T, Isozaki T, Matsunawa M
Arthritis Res Ther. 2004; 6(1):R78-R86.
PMID: 14979941
PMC: 400420.
DOI: 10.1186/ar1029.
SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus.
Aringer M, Smolen J
Arthritis Res Ther. 2003; 5(4):172-7.
PMID: 12823847
PMC: 165063.
DOI: 10.1186/ar770.
Therapy of systemic lupus erythematosus: a look into the future.
Smolen J
Arthritis Res. 2002; 4 Suppl 3:S25-30.
PMID: 12110120
PMC: 3240154.
DOI: 10.1186/ar579.
The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity.
Theofilopoulos A, Koundouris S, Kono D, Lawson B
Arthritis Res. 2001; 3(3):136-41.
PMID: 11299053
PMC: 128889.
DOI: 10.1186/ar290.
The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.
Horwitz D, Jacob C
Springer Semin Immunopathol. 1994; 16(2-3):181-200.
PMID: 7716704
DOI: 10.1007/BF00197516.
Drug-induced lupus.
Price E, Venables P
Drug Saf. 1995; 12(4):283-90.
PMID: 7646827
DOI: 10.2165/00002018-199512040-00008.
Clinical toxicity of the interferons.
Vial T, Descotes J
Drug Saf. 1994; 10(2):115-50.
PMID: 7516663
DOI: 10.2165/00002018-199410020-00003.